Výsledky vyhledávání - "Ignatius, Thomas"

Effects of BG9928, an Adenosine A1Receptor Antagonist, in Patients With Congestive Heart Failure

Autor: William B. Smith, Steven Goldman, Stuart D. Russell, Douglas Chapman, Barry Ticho, Aaron Deykin, Stephen S. Gottlieb, Ignatius Thomas, David DeNofrio, William T. Abraham

Publikováno v: The Journal of Clinical Pharmacology. 51:899-907

Previous studies suggest that adenosine A 1 receptor antagonists may promote natriuresis without deleterious effects on renal function. This study evaluated renal and hemodynamic effects as well as safety, pharmacokinetics, and tolerability of BG9928

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dbbb81883243a2a392fe47833dafa66b
https://doi.org/10.1177/0091270010375957

Zobrazit plný text záznamu

Effects of Multiple Oral Doses of an A1Adenosine Antagonist, BG9928, in Patients With Heart Failure

Autor: Ying Zhu, Barry H. Greenberg, Ignatius Thomas, Barry M. Massie, Barry Ticho, Steven Goldman, William T. Abraham, Dorothy Banish, Edward P. Havranek

Publikováno v: Journal of the American College of Cardiology. 50(7):600-606

Effects of Multiple Oral Doses of an A1 Adenosine Antagonist, BG9928, in Patients With Heart Failure: Results of a Placebo-Controlled, Dose-Escalation StudyBarry Greenberg, Ignatius Thomas, Dorothy...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e237baa625279bcbb3d0abb2156a1e4

Zobrazit plný text záznamu

BG9719 (CVT-124), an A 1 Adenosine Receptor Antagonist, Protects Against the Decline in Renal Function Observed With Diuretic Therapy

Autor: Ignatius Thomas, Robert C. Bourge, Farere Dyer, William T. Abraham, Edward P. Havranek, Miguel Gomez, Stephen S. Gottlieb, D. Craig Brater, Evan Beckman, Donald Bennett, Steven Goldman, Barry Ticho

Publikováno v: Circulation. 105:1348-1353

Background — Adenosine may adversely affect renal function via its effects on renal arterioles and tubuloglomerular feedback, but effects of adenosine blockade in humans receiving furosemide and ACE inhibitors is unknown. Methods and Results — Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3686aabf5aa0fadb0bbb6f06cc157f51
https://doi.org/10.1161/hc1102.105264

Zobrazit plný text záznamu

Acute Hemodynamic Effects of Conivaptan, a Dual V 1A and V 2 Vasopressin Receptor Antagonist, in Patients With Advanced Heart Failure

Autor: Francoise Chanoine, William B. Smith, Jalal K. Ghali, Maha Ghazzi, Grady H. Hendrix, Milton L. Pressler, James E. Udelson, Christopher A. Painchaud, Ignatius Thomas, Marvin A. Konstam, Paulina Selaru

Publikováno v: Circulation. 104:2417-2423

Background Arginine vasopressin may contribute to abnormalities in hemodynamics and fluid balance in heart failure through its actions on V 1A (vascular and myocardial effects) and V 2 receptors (renal effects). Inhibiting the action of vasopressin m

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ee01e07a62869953d8c62d869c45622
https://doi.org/10.1161/hc4501.099313

Zobrazit plný text záznamu

Effects of omapatrilat on hemodynamics and safety in patients with heart failure

Autor: Martin S. Bilsker, J. Thomas Heywood, Alan Niederman, David Synhorst, Bruce J Iteld, George A Ponce, Marc Klapholz, Ignatius Thomas, Calvin Eng

Publikováno v: The American Journal of Cardiology. 88:657-661

Omapatrilat, a novel vasopeptidase inhibitor, is a highly potent and selective inhibitor of neutral endopeptidase and angiotensin-converting enzyme; its therapeutic potential is being investigated for treatment of hypertension and heart failure. In t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ddbc0d4bd6cd251fcbfdc2bc66ef16dc
https://doi.org/10.1016/s0002-9149(01)01809-4

Zobrazit plný text záznamu

Autor: Robert Wolf, Ignatius Thomas, Martin S. Bilsker, Edward P. Havranek, George A Ponce, Mark A. Munger, William B. Smith

Publikováno v: Journal of the American College of Cardiology. 33:1174-1181

OBJECTIVES The primary purpose of this study was to determine the acute and long-term hemodynamic and clinical effects of irbesartan in patients with heart failure. BACKGROUND Inhibition of angiotensin II production by angiotensin-converting enzyme (

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f7e5f16626abb44b2ab827f801ce94b7
https://doi.org/10.1016/s0735-1097(98)00695-0

Zobrazit plný text záznamu

Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)

Autor: Paul I Chang, Dawn E Ney, Duane B. Snavely, Alan J. Cowley, Prakash Deedwania, Ignatius Thomas, Bertram Pitt, Felipe Martinez, Robert Segal, Georg Meurers

Publikováno v: The Lancet. 349:747-752

Summary Background To determine whether specific angiotensin II receptor blockade with losartan offers safety and efficacy advantages in the treatment of heart failure over angiotensin-converting-enzyme (ACE) inhibition with captopril, the ELITE stud

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de3d5dcd65df3fc038671814c63a71e4
https://doi.org/10.1016/s0140-6736(97)01187-2

Zobrazit plný text záznamu

Plný text ve formátu HTML

A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction

Autor: Terrence X. O'Brien, Paul J. Hauptman, James E. Udelson, Ignatius Thomas, Martin Bilsker, Christopher Zimmer, Cesare Orlandi, Rafael F. Sequeira, Marvin A. Konstam

Publikováno v: Journal of cardiac failure. 17(12)

Increased vasopressin levels may be present in patient with chronic heart failure (HF) and contribute to pathophysiology through effects on the vasopressin V2 receptor. The presence of background diuretic therapy may confound evaluations of vasopress

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19bfc420e1d52a3c4bbfce1cab83a8a1
https://pubmed.ncbi.nlm.nih.gov/22123360

Zobrazit plný text záznamu

Effects of BG9928, an adenosine A₁ receptor antagonist, in patients with congestive heart failure

Autor: Stephen S, Gottlieb, Barry, Ticho, Aaron, Deykin, William T, Abraham, David, Denofrio, Stuart D, Russell, Douglas, Chapman, William, Smith, Steven, Goldman, Ignatius, Thomas

Publikováno v: Journal of clinical pharmacology. 51(6)

Previous studies suggest that adenosine A₁ receptor antagonists may promote natriuresis without deleterious effects on renal function. This study evaluated renal and hemodynamic effects as well as safety, pharmacokinetics, and tolerability of BG992

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::3a8204c08482bdd65e192cd32db97b85
https://pubmed.ncbi.nlm.nih.gov/20926754

Zobrazit plný text záznamu

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study

Autor: Barry, Greenberg, Ignatius, Thomas, Dorothy, Banish, Steven, Goldman, Edward, Havranek, Barry M, Massie, Ying, Zhu, Barry, Ticho, William T, Abraham

Publikováno v: Journal of the American College of Cardiology. 50(7)

This study sought to assess the pharmacokinetics and clinical effects of oral BG9928 in heart failure (HF) patients.Declining renal function during HF treatment is associated with poor outcomes. BG9928, a selective inhibitor of the A1 adenosine recep

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::65f60c92bef448be2b36cc1e47eda1bf
https://pubmed.ncbi.nlm.nih.gov/17692744

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání